These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 37230537)
1. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537 [TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
3. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987 [TBL] [Abstract][Full Text] [Related]
4. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. Luo Y; Shreeder B; Jenkins JW; Shi H; Lamichhane P; Zhou K; Bahr DA; Kurian S; Jones KA; Daum JI; Dutta N; Necela BM; Cannon MJ; Block MS; Knutson KL J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918918 [TBL] [Abstract][Full Text] [Related]
5. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]
6. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461 [TBL] [Abstract][Full Text] [Related]
7. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092 [TBL] [Abstract][Full Text] [Related]
8. Immune effects of CDK4/6 inhibitors in patients with HR Scirocchi F; Scagnoli S; Botticelli A; Di Filippo A; Napoletano C; Zizzari IG; Strigari L; Tomao S; Cortesi E; Rughetti A; Marchetti P; Nuti M EBioMedicine; 2022 May; 79():104010. PubMed ID: 35477069 [TBL] [Abstract][Full Text] [Related]
9. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. He M; Roussak K; Ma F; Borcherding N; Garin V; White M; Schutt C; Jensen TI; Zhao Y; Iberg CA; Shah K; Bhatia H; Korenfeld D; Dinkel S; Gray J; Ulezko Antonova A; Ferris S; Donermeyer D; Lindestam Arlehamn C; Gubin MM; Luo J; Gorvel L; Pellegrini M; Sette A; Tung T; Bak R; Modlin RL; Fields RC; Schreiber RD; Allen PM; Klechevsky E Science; 2023 Feb; 379(6633):eabg2752. PubMed ID: 36795805 [TBL] [Abstract][Full Text] [Related]
10. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836 [TBL] [Abstract][Full Text] [Related]
12. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484 [TBL] [Abstract][Full Text] [Related]
13. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Uzhachenko RV; Bharti V; Ouyang Z; Blevins A; Mont S; Saleh N; Lawrence HA; Shen C; Chen SC; Ayers GD; DeNardo DG; Arteaga C; Richmond A; Vilgelm AE Cell Rep; 2021 Apr; 35(1):108944. PubMed ID: 33826903 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related]
15. Exercise Training Improves Tumor Control by Increasing CD8 Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer. Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797 [TBL] [Abstract][Full Text] [Related]
17. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722 [TBL] [Abstract][Full Text] [Related]
18. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation. Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159 [TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541 [TBL] [Abstract][Full Text] [Related]
20. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]